Table 1. Characteristics of the study population.
| Elderly (≥ 65 years) n = 120 |
Younger (<65 years) n = 380 |
Elderly (>75 years) n = 37 |
|
|---|---|---|---|
| Demographic characteristics | |||
| Age, years (mean ± SDa) | 72.6 ± 7.4 | 51.2 ± 7.1 | 78.8 ± 3.3 |
| Gender, n (%) | |||
| Men | 57 (47.5) | 298 (78.4) | 20 (54.1) |
| Virological characteristics and liver status | |||
| Genotype, n (%) | |||
| 1a | 7 (5.8) | 102 (26.8) | 2 (5.4) |
| 1b | 100 (83.3) | 133 (35.1) | 33 (89.2) |
| 1 Unknown subtype | 8 (6.8) | 0 | 1 (2.7) |
| 2 | 3 (2.5) | 15 (3.9) | 1 (2.7) |
| 3 | 1 (0.8) | 70 (18.4) | 0 |
| 4 | 1 (0.8) | 60 (15.8) | 0 |
| Stiffnessb, kPa, (median, IQR) | 16.0 (10.0–21.4) | 12.5 (9.9–20.0) | 16.9 (12.0–21.9) |
| F2, n (%) | 18 (15.0) | 72 (18.9) | 5 (13.5) |
| F3, n (%) | 25 (20.8) | 146 (38.4) | 4 (10.8) |
| F4, n (%) | 77 (64.2) | 162 (42.7) | 28 (75.7) |
| SVR12c, n (%) | 111 (99.1) | 326 (97.4) | 30 (100) |
| Clinical and liver-related events, n (%) | |||
| Liver-related events | 7 (5.8) | 9 (2.4) | 4 (10.8) |
| Any tumour | 9 (7.5) | 13 (3.4) | 4 (10.8) |
| HCCd | 5 (4.2) | 9 (2.4) | 2 (5.4) |
| Liver decompensation | 4 (3.3) | 4 (1.1) | 1 (2.7) |
| Hydropic decompensation | 2 (1.6) | 2 (0.5) | 0.0 |
| Upper bleeding | 1 (0.8) | 1 (0.3) | 0.0 |
| Encephalopathy | 1 (0.8) | 1 (0.3) | 1 (2.7) |
| All-cause mortality | 10 (8.3) | 8 (2.1) | 6 (16.2) |
| Liver-related death | 3 (2.5) | 2 (0.5) | 1 (2.7) |
| Liver transplantation | 0.0 | 4 (1.1) | 0.0 |
aSD: standard deviation
bmeasured using the Fibroscan
cSVR12: sustained virological response after 12 weeks from end of treatment
dHCC: hepatocellular carcinoma.